Myelodysplastic Syndrome Treatment Market

Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more often in older men than women. This syndrome is characterized by certain chromosomal mutations in Janus Kinase gene which include deletion of q arm in one or more chromosomes and complete deletion of chromosome 5 or 7 and an extra copy of chromosome 8.

Myelodysplastic Syndrome Treatment Market contains market size and forecasts of Myelodysplastic Syndrome (MDS) Treatment in global, including the following market information:

Global Myelodysplastic Syndrome (MDS) Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Myelodysplastic Syndrome (MDS) Treatment Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Myelodysplastic Syndrome (MDS) Treatment companies in 2021 (%)

The global Myelodysplastic Syndrome (MDS) Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Azacitidine Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Myelodysplastic Syndrome (MDS) Treatment include Novartis AG, Celgene Corporation, Otsuka Pharmaceutical Co., Ltd, Sandoz Inc, Dr Reddys Laboratories Limited, Pharmascience Inc, Accord Healthcare Ltd and Mylan N.V., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Myelodysplastic Syndrome (MDS) Treatment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Myelodysplastic Syndrome (MDS) Treatment Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Myelodysplastic Syndrome (MDS) Treatment Market Segment Percentages, by Type, 2021 (%)

Azacitidine

Lenalidomide

Decitabine

Deferasirox

Global Myelodysplastic Syndrome (MDS) Treatment Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Myelodysplastic Syndrome (MDS) Treatment Market Segment Percentages, by Application, 2021 (%)

Refractory Cytopenia with Unilineage Dysplasia

Refractory Anemia with Ringed Sideroblasts

Others

Global Myelodysplastic Syndrome (MDS) Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Myelodysplastic Syndrome (MDS) Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Myelodysplastic Syndrome (MDS) Treatment revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Myelodysplastic Syndrome (MDS) Treatment revenues share in global market, 2021 (%)

Key companies Myelodysplastic Syndrome (MDS) Treatment sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Myelodysplastic Syndrome (MDS) Treatment sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Novartis AG

Celgene Corporation

Otsuka Pharmaceutical Co., Ltd

Sandoz Inc

Dr Reddys Laboratories Limited

Pharmascience Inc

Accord Healthcare Ltd

Mylan N.V.